Holen Sie sich die Stockscreener-App
1.0003
0.50%
-0.0097
Schlusskurs vom Vortag:
$1.01
Offen:
$1.01
24-Stunden-Volumen:
82,481
Relative Volume:
0.07
Marktkapitalisierung:
$95.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.58M
KGV:
-3.8816
EPS:
-0.2577
Netto-Cashflow:
$-20.25M
1W Leistung:
-4.29%
1M Leistung:
-6.94%
6M Leistung:
-6.94%
1J Leistung:
-60.28%
1-Tages-Spanne:
$1.00
$1.03
1-Wochen-Bereich:
$1.00
$1.06
52-Wochen-Spanne:
$0.5501
$2.60
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.0015 | 96.04M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
522.72 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.64 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
An Alzheimer's drug will be discussed Sept. 15 by Cognition Therapeutics - Stock Titan
Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cognition (CGTX) Earnings Report: Reported EPS Tops Expectations; Market Reaction: Shares Move 0.22% Lower in the Latest ReadingPreliminary Results - vinanet.vn
Cognition Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat
Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Dealer Delta - vinanet.vn
Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat
Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cognition Therapeutics Inc (CGTX) Stock News Today - TradingKey
Cognition Therapeutics Stock (CGTX) Opinions on biotech upside speculation - Quiver Quantitative
Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cognition Therapeutics, Inc. (CGTX) latest stock news and headlines - Yahoo Finance UK
Cognition Therapeutics Inc Q2 2026: Net loss $(3.9M), EPS $(0.04) — 10-Q Summary - TradingView
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics Q2 EPS beats estimate as R&D cuts narrow losses - scanx.trade
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cognition Therapeutics reports Q2 2026 net loss $3.9M, cash $34.8M; plans Phase 3 in DLB psychosis - TradingView
Cognition Therapeutics Q2 net loss narrows on lower R&D costs - TradingView
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - Yahoo Finance
Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight - Yahoo Finance
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Edges Higher as Traders Eye Key Resistance LevelsAdvance Decline Volume - vinanet.vn
Cognition Therapeutics (NASDAQ:CGTX) Trading Up 3.3%Time to Buy? - MarketBeat
Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey
CGTX|Cognition Therapeutics Inc|Price:1.020|Chg%:-0.040 - tradingkey.com
Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey
Cognition Therapeutics Inc (CGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey
Cognition Therapeutics Inc (CGTX) Income Statement - TradingKey
Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView
CGTX|Cognition Therapeutics Inc|Price:0.982|Chg%:-0.038 - TradingKey
CGTX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Progress in Alzheimer’s PipelineRevenue Growth Outlook - vinanet.vn
Cognition Therapeutics (CGTX) Slips 4% as Support Level Comes Into FocusRunaway Gap - vinanet.vn
Cognition Therapeutics (CGTX) Q2 2024 earnings summary - Quartr
CGTX Q1 2026 Earnings: Narrower Loss Bolsters Cash Runway as Alzheimer’s Trials ContinueGuidance Revision Trend - vinanet.vn
CGTX Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline advancesEstimate Accuracy - po-news-eg.net
Cognition Therapeutics (CGTX) Edges Higher as Biotech Stock Tests Key ResistanceAnalyst Upgrade Stocks - dars.gov.et
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - Sahm
Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key Support LevelRVOL Breakout - dars.gov.et
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside Discussion - Quiver Quantitative
Alzheimer’s drug developer to outline Lewy body dementia Phase 3 plan - Stock Titan
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit - Yahoo Finance
Enterprise value to EBIT forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Can AI automation provide a survival tool amid managed care's thin margins? (CVS:NYSE) - Seeking Alpha
Enterprise value to revenue forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):